Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRCA1/2”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT03140670
What this trial is testing

Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy

Who this might be right for
Pancreatic Cancer
Abramson Cancer Center at Penn Medicine 46
Testing effectiveness (Phase 2)Study completedNCT02789332
What this trial is testing

Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency

Who this might be right for
Breast CancerTriple Negative Breast NeoplasmsHRpos Breast Neoplasms+1 more
GBG Forschungs GmbH 107
Not applicableStudy completedNCT02372864
What this trial is testing

Psychosexual Consequences of Risk-reducing Salpingo-oophorectomy

Who this might be right for
Ovarian Cancer
University Medical Center Groningen 66
Testing effectiveness (Phase 2)Study completedNCT02797977
What this trial is testing

A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects

Who this might be right for
Advanced Solid Tumors
Sierra Oncology LLC - a GSK company 153
Testing effectiveness (Phase 2)Ended earlyNCT02326844
What this trial is testing

BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment

Who this might be right for
Ovarian Cancer
National Cancer Institute (NCI) 3
Testing effectiveness (Phase 2)UnknownNCT04556292
What this trial is testing

A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer Patients

Who this might be right for
Breast Cancer MetastaticBRCA 1 Gene MutationBRCA 2 Gene Mutation
Jiangxi Qingfeng Pharmaceutical Co. Ltd. 78
Testing effectiveness (Phase 2)Study completedNCT01009788
What this trial is testing

ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer

Who this might be right for
Breast CancerMetastatic Breast CancerBRCA1 Gene Mutation+1 more
Steven J Isakoff, MD, PhD 63
Testing effectiveness (Phase 2)Active Not RecruitingNCT02286687
What this trial is testing

Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes

Who this might be right for
Advanced Malignant NeoplasmATM Gene MutationBRCA1 Gene Mutation+5 more
M.D. Anderson Cancer Center 150
Not applicableUnknownNCT02516540
What this trial is testing

Efficacy of Lifestyle Intervention in BRCA1/2 Mutation Carriers

Who this might be right for
Hereditary Breast and Ovarian Cancer
Technical University of Munich 600
Not applicableStudy completedNCT02451735
What this trial is testing

Genetic Counseling for Breast Cancer Survivors (GC for BC)

Who this might be right for
Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute 157
Not applicableStudy completedNCT01866865
What this trial is testing

Adaptation to Living With a BRCA1/2 Mutation

Who this might be right for
Cancer Genetics
National Human Genome Research Institute (NHGRI) 142
Testing effectiveness (Phase 2)Ended earlyNCT03442556
What this trial is testing

Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency

Who this might be right for
ATM Gene MutationBRCA1 Gene MutationBRCA2 Gene Mutation+7 more
University of Washington 18
Testing effectiveness (Phase 2)UnknownNCT03337087
What this trial is testing

Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer

Who this might be right for
Metastatic Biliary Tract CarcinomaMetastatic Colorectal CarcinomaMetastatic Gastroesophageal Junction Adenocarcinoma+6 more
Academic and Community Cancer Research United 18
Testing effectiveness (Phase 2)Looking for participantsNCT06201234
What this trial is testing

Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer

Who this might be right for
Hormone Receptor Positive HER-2 Negative Breast CancerAdvanced or Metastatic Breast CancerBRCA1 Mutation+1 more
GBG Forschungs GmbH 176
Not applicableLooking for participantsNCT03396341
What this trial is testing

Responses to Genetic Risk Modifier Testing Among Women With Pathogenic Variants in Breast Cancer Predisposition Genes

Who this might be right for
Genetic TestingBRCA1/2
Memorial Sloan Kettering Cancer Center 806
Not applicableEnded earlyNCT01103128
What this trial is testing

Validation of a Mouse Model of Pancreatic Carcinogenesis

Who this might be right for
Pancreatic Cancer
Columbia University 450
Testing effectiveness (Phase 2)Study completedNCT01506609
What this trial is testing

Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
AbbVie 294
Not applicableStudy completedNCT06429644
What this trial is testing

Long-term Oncologic Outcome of Breast-conserving Surgery in Breast Cancer Patients With BRCA1/2 Mutations

Who this might be right for
BRCA1/2 MutationBreast-conserving Surgery
Hanyang University Seoul Hospital 4,010
Not applicableStudy completedNCT02206360
What this trial is testing

Pancreatic Cancer Early Detection Program

Who this might be right for
Pancreatic CancerPancreas CancerPancreatic Adenocarcinoma+8 more
White Plains Hospital 181
Post-approval studies (Phase 4)Active Not RecruitingNCT05457257
What this trial is testing

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
AstraZeneca 43
Next Page